Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects

Status Recruiting

Clinical Trial Summary

The purpose of this study is to explore the effect of Lisdexamfetamine on Prefrontal Brain Dysfunction in Binge Eating Disorder

Clinical Trial Description

12-week, open-label LDX trial for BED including fMRI assessments to test the following specific predictions:

1. At baseline, patients with BED will show greater ventral prefrontal, striatal, and amygdala brain activation to high-calorie food pictures (reward) than matched healthy comparison subjects.

2. After 12 weeks of LDX treatment, BED will exhibit reduced ventral prefrontal, striatal and amygdala brain activation to food cues compared to baseline.

3. BED patients who display cessation of binge eating and those who demonstrate clinical improvement after 12 weeks of LDX treatment will show greater reductions in ventral prefrontal, striatal, and amygdala brain activation to food pictures than patients who do not stop binge eating and those who do not improve, respectively. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02659488
Study type	Interventional
Source	Lindner Center of HOPE
Contact	Anna Guerdjikova, PhD, LISW
Phone	513-536-0700
Email	anna.guerdjikova@lindnercenter.org
Status	Recruiting
Phase	Phase 2
Start date	September 2015
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02978742` - Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder	N/A
Completed	`NCT02659475` - Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)	Phase 2
Completed	`NCT00601653` - Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder	N/A
Completed	`NCT02834299` - Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder	N/A
Completed	`NCT02553824` - FDA Approved Medication to Reduce Binge Eating and/or Purging	Phase 1
Completed	`NCT02564588` - Dasotraline Binge Eating Disorder Study	Phase 2/Phase 3
Completed	`NCT00307190` - Hormone Release and Stomach Disturbances in People With Binge Eating Disorder	N/A
Completed	`NCT01718483` - SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder	Phase 3
Completed	`NCT01718509` - SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder	Phase 3
Completed	`NCT02503098` - Optimizing a Smartphone Application for Individuals With Eating Disorders	N/A
Active, not recruiting	`NCT01837953` - Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial	N/A
Completed	`NCT01010789` - Armodafinil in Binge Eating Disorder (BED)	Phase 3
Completed	`NCT01098435` - ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder	Phase 2
Completed	`NCT01552759` - Appetite Hormones in Binge Eating Disorder	N/A
Completed	`NCT00330655` - An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder	Phase 4
Completed	`NCT01291173` - Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder	Phase 2
Completed	`NCT03107026` - A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder	Phase 3
Completed	`NCT02079935` - Treatment of Eating Disorders by Physical Activity and Nutrition Counseling	N/A
Completed	`NCT00277641` - Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity	Phase 3
Completed	`NCT00032760` - Meditation-Based Treatment for Binge Eating Disorder	Phase 2/Phase 3